{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:29:02Z","timestamp":1786768142539,"version":"build-2736575974"},"reference-count":44,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,8,15]]},"DOI":"10.2169\/internalmedicine.6630-25","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T22:26:45Z","timestamp":1766615205000},"page":"2256-2261","source":"Crossref","is-referenced-by-count":1,"title":["Rituximab-induced Acute Thrombocytopenia in Systemic Sclerosis: A Case Report of Two Cases"],"prefix":"10.2169","volume":"65","author":[{"given":"Chihiro","family":"Saiki","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"},{"name":"Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ayano","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyasu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Niiro","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Denton CP, Khanna D. Systemic sclerosis. Lancet 390: 1685-1699, 2017.","DOI":"10.1016\/S0140-6736(17)30933-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S. Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford) 58: 567-579, 2019.","DOI":"10.1093\/rheumatology\/key151"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 11: 45-54, 2023.","DOI":"10.1016\/S2213-2600(22)00359-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Del Galdo F, Lescoat A, Conaghan PG, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84: 29-40, 2025.","DOI":"10.1136\/ard-2024-226430"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221-232, 2010.","DOI":"10.1056\/NEJMoa0909905"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tanaka Y, Takeuchi T, Miyasaka N, et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol 26: 80-86, 2016.","DOI":"10.3109\/14397595.2015.1060665"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nitta E, Izutsu K, Sato T, et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 18: 364-369, 2007.","DOI":"10.1093\/annonc\/mdl393"},{"key":"8","unstructured":"8. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 205: e18-e47, 2022."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Henter JI, Horne A, Aric\u00f3 M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48: 124-131, 2007.","DOI":"10.1002\/pbc.21039"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 66: 2613-2620, 2014.","DOI":"10.1002\/art.38690"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Rigamonti C, Volta C, Colombi S, et al. Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion. Leukemia 15: 186-187, 2001.","DOI":"10.1038\/sj.leu.2401987"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Shah C, Grethlein SJ. Case report of rituximab-induced thrombocytopenia. Am J Hematol 75: 263, 2004.","DOI":"10.1002\/ajh.20028"},{"key":"13","unstructured":"13. Otrock ZK, Mahfouz RA, Oghlakian GO, et al. Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica 90 (Suppl): ECR23, 2005."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Rosado M, Chao H, Rose M. Severe acute thrombocytopenia following rituximab therapy. Leuk Lymphoma 48: 2239-2240, 2007.","DOI":"10.1080\/10428190701625099"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Dhand S, Bahrain H. Rituximab-induced severe acute thrombocytopenia: a case report and review of literature. Cancer Invest 26: 913-915, 2008.","DOI":"10.1080\/07357900802010509"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ram R, Bonstein L, Gafter-Gvili A, Ben-Bassat I, Shpilberg O, Raanani P. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. Am J Hematol 84: 247-250, 2009.","DOI":"10.1002\/ajh.21372"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yi JH, Kim SJ, Ahn HK, Lee SJ, Chang MH, Kim WS. Rituximab-induced acute thrombocytopenia: a case report and review of the literature. Med Oncol 26: 45-48, 2009.","DOI":"10.1007\/s12032-008-9079-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Adiyodi J, Thachil J, Hawkins S, Hincks I, Woodcock BE, Salim R. Thrombocytopenia with rituximab treatment - splenomegaly as the risk factor. Ann Hematol 89: 95-96, 2010.","DOI":"10.1007\/s00277-009-0768-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Parajuli R, Hire E, Shah BK. Rituximab-induced acute severe thrombocytopenia. Br J Haematol 149: 804, 2010.","DOI":"10.1111\/j.1365-2141.2010.08119.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sadashiv SK, Rao R, Fazal S, Lister J. Rituximab-induced acute severe thrombocytopenia: a case series in patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 13: 602-605, 2013.","DOI":"10.1016\/j.clml.2013.04.013"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. El-Osta H, Nair B. Rituximab-induced acute thrombocytopenia: an underappreciated entity. Leuk Lymphoma 54: 2736-2737, 2013.","DOI":"10.3109\/10428194.2013.784972"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ureshino H, Nishioka A, Kojima K, et al. Rituximab-induced acute thrombocytopenia in high tumor burden follicular lymphoma. Intern Med 55: 2061-2064, 2016.","DOI":"10.2169\/internalmedicine.55.6140"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Omura Y, Shimazu H, Takahashi T. Rituximab-induced acute thrombocytopenia in a patient with follicular lymphoma: a case report and review of the literature. Intern Med 57: 1151-1154, 2018.","DOI":"10.2169\/internalmedicine.9628-17"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Qureini A, Asif S, Harry S, Madhusudhana S. A case of rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma and chronic hepatitis C virus infection. Am J Case Rep 20: 1394-1397, 2019.","DOI":"10.12659\/AJCR.917644"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Williams J, Chiruka S. Spontaneous splenic rupture and rituximab-induced acute thrombocytopenia in a patient with high-risk mantle cell lymphoma. Case Rep Hematol 2019: 2429098, 2019.","DOI":"10.1155\/2019\/2429098"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Jiang Y, Song J, Wang N, et al. Rituximab-induced acute thrombocytopenia in patients with splenomegaly B Cell lymphoma: an underdiagnosed but severe complication. Cancer Biol Ther 21: 1060-1066, 2020.","DOI":"10.1080\/15384047.2020.1832017"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Robinson AC, Nachar VR. Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma. J Oncol Pharm Pract 26: 1248-1253, 2020.","DOI":"10.1177\/1078155219890023"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kars TU, Yorganc\u0131 ZF, Ya\u015fk\u0131ran O, Tekinalp A, Demircio\u011flu S. Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma. J Oncol Pharm 29: 1011-1014, 2023.","DOI":"10.1177\/10781552221142870"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Haage TR, Zeremski V, Berisha M, Mougiakakos D. Hypogammaglobulinemia and anti-CD20 therapy-induced acute thrombocytopenia: perhaps more than a coincidence? Oncol Res Treat 47: 434-438, 2024.","DOI":"10.1159\/000539919"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Brustugun OT, Nielsen EW. Acquired angioedema and rituximab-induced acute thrombocytopenia in splenic marginal zone lymphoma. Acta Oncol 64: 868-871, 2025.","DOI":"10.2340\/1651-226X.2025.43897"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Pamuk GE, Donmez S, Turgut B, Demir M, Vural O. Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia. Am J Hematol 78: 81, 2005.","DOI":"10.1002\/ajh.20218"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Thachil J, Mukherje K, Woodcock B. Rituximab-induced haemorrhagic thrombocytopenia in a patient with hairy cell leukaemia. Br J Haematol 135: 273-274, 2006.","DOI":"10.1111\/j.1365-2141.2006.06299.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kotsianidis I, Goutzouvelidis A, Anastasiades A, et al. Severe thrombocytopenia and fibrinolysis mimicking disseminated intravascular coagulation after rituximab infusion. Am J Hematol 85: 146, 2010.","DOI":"10.1002\/ajh.21597"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Rafei H, Nassereddine S, Garcia IF. Disseminated intravascular coagulation-like reaction following rituximab infusion. BMJ Case Rep 2017: bcr2016218443, 2017.","DOI":"10.1136\/bcr-2016-218443"},{"key":"35","unstructured":"35. Larrar S, Guitton C, Willems M, Bader-Meunier B. Severe hematological side effects following rituximab therapy in children. Haematologica 91: 101, 2006."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Endo Y, Koga T, Ishida M, et al. Rituximab-induced acute thrombocytopenia in granulomatosis with polyangiitis. Intern Med 57: 2247-2250, 2018.","DOI":"10.2169\/internalmedicine.0335-17"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Yudhishdran J, Sivakumar J, Navinan MR, Bandapatti S. Rituximab induced acute thrombocytopenia in a patient with systemic lupus erythematosus: a case report. J Med Case Rep 15: 339, 2021.","DOI":"10.1186\/s13256-021-02950-y"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Mankikian J, Caille A, Reynaud-Gaubert M, et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J 61: 2202071, 2023.","DOI":"10.1183\/13993003.02071-2022"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 3: e489-e497, 2021.","DOI":"10.1016\/S2665-9913(21)00107-7"},{"key":"40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"40. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells <i>in vivo<\/i> by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445, 1994.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Shibazaki M, Kawabata Y, Yokochi T, Nishida A, Takada H, Endo Y. Complement-dependent accumulation and degradation of platelets in the lung and liver induced by injection of lipopolysaccharides. Infect Immun 67: 5186-5191, 1999.","DOI":"10.1128\/IAI.67.10.5186-5191.1999"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Michelmann I, B\u00f6ckmann D, N\u00fcrnberger W, Eckhof-Donovan S, Burdach S, G\u00f6bel U. Thrombocytopenia and complement activation under recombinant TNF\u03b1\/IFN\u03b3 therapy in man. Ann Hematol 4: 179-184, 1997.","DOI":"10.1007\/s002770050279"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Juluri KR, Wu QV, Voutsinas J, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv 6: 2055-2068, 2022.","DOI":"10.1182\/bloodadvances.2020004142"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3: 3829-3866, 2019.","DOI":"10.1182\/bloodadvances.2019000966"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/16\/65_6630-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:11:52Z","timestamp":1786767112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/16\/65_6630-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":44,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6630-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"article-number":"6630-25"}}